COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #140 of 230
9/24 Late treatment study
Shoaibi et al., medRxiv, doi:10.1101/2020.09.23.20199463 (Preprint)
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients
Source   PDF   Share   Tweet
Retrospective database analysis focused on Famotidine but also showing results for HCQ users, with unadjusted mortality RR 0.85, p<0.001 (13.6% vs. 16.1%).

Shoaibi et al., 9/24/2020, retrospective, database analysis, USA, North America, preprint, 5 authors.
risk of death, 15.4% lower, RR 0.85, p < 0.001, treatment 686 of 5047 (13.6%), control 3923 of 24404 (16.1%).
Details of all 230 studies    Meta analysis
Please submit corrections, updates, or comments.
Submit